{
"id":"mk19_b_hm_s9",
"subspecialtyId":"hm",
"title":"Thrombotic Disorders",
"jsonContent":{
"type":"section",
"id":"mk19_b_hm_s9",
"title":{
"__html":"Thrombotic Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"b8db1b",
"children":[
"Thrombotic Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s9_0",
"children":[
{
"type":"p",
"hlId":"b290ca",
"children":[
"The burden of venous thromboembolic disease, including superficial and deep venous thrombosis (DVT) and pulmonary embolism (PE), continues to increase despite better awareness of risk factors and prevention options. The incidence of a first episode of venous thromboembolism (VTE) is approximately 1 to 2 per 1000 person/years."
]
},
{
"type":"p",
"hlId":"d145fb",
"children":[
"Many nosocomial VTEs are preventable, although thromboprophylaxis continues to be underused. D-dimer testing and imaging for VTE diagnosis should be used within the context of appropriate clinical algorithms."
]
},
{
"type":"p",
"hlId":"92bc33",
"children":[
"Opinions differ regarding the relevance of thrombophilia testing, and results usually do not affect treatment choices. Treatment options continue to evolve."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_1",
"title":{
"__html":"Pathophysiology of Thrombosis"
},
"titleNode":{
"type":"section-title",
"hlId":"faba6a",
"children":[
"Pathophysiology of Thrombosis"
]
},
"children":[
{
"type":"p",
"hlId":"5470b3",
"children":[
"Alterations in three primary physiologic processes predispose persons to VTE. The Virchow triad, described by Rudolph Virchow more than 150 years ago, includes reduced or turbulent blood flow, alterations or injury to the vessel wall, and changes in blood components that are prothrombotic or inhibit fibrinolysis (or both). VTE usually develops from the synergistic effect of multiple risk factors."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2",
"title":{
"__html":"Thrombophilia"
},
"titleNode":{
"type":"section-title",
"hlId":"7cb141",
"children":[
"Thrombophilia"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s9_2_1",
"title":{
"__html":"Thrombophilia Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"89e412",
"children":[
"Thrombophilia Testing"
]
},
"children":[
{
"type":"p",
"hlId":"aa028f",
"children":[
"One aspect of the Virchow triad is hypercoagulability, or thrombophilia. Thrombophilia can be inherited or acquired. Although guidelines differ, most experts agree that thrombophilia evaluation should not be routinely pursued in patients with VTE but may be considered in certain populations, including patients with thromboses at unusual sites (e.g., the portal venous system) or recurrent idiopathic thrombosis, patients younger than 45 years with unprovoked thrombosis, patients with a clear family history of thrombosis in one or more first-degree relatives, women with a history of recurrent fetal loss, and patients with warfarin-induced skin necrosis."
]
},
{
"type":"p",
"hlId":"b3915b",
"children":[
"Many variables, including acute thrombosis and anticoagulant use, can affect outcomes of thrombophilia testing and may lead to false-positive test results. Except for high-risk antiphospholipid antibody syndrome, a known thrombophilia will not change immediate management; therefore, testing should not be pursued in the acute setting."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"3d29db",
"children":[
"Thrombophilia testing may be considered in patients with thromboses at unusual sites or recurrent idiopathic thrombosis, patients younger than 45 years with unprovoked thrombosis, patients with a clear family history of thrombosis in one or more first-degree relatives, women with a history of recurrent fetal loss, and patients with warfarin-induced skin necrosis."
]
},
{
"type":"keypoint",
"hlId":"022822",
"hvc":true,
"children":[
"Thrombophilia testing is less accurate during episodes of acute venous thromboembolism, and results generally do not change immediate management, except in high-risk antiphospholipid antibody syndrome; if thrombophilia testing is indicated, it should ideally be performed after anticoagulation has been discontinued."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_2",
"title":{
"__html":"Inherited Thrombophilias"
},
"titleNode":{
"type":"section-title",
"hlId":"6cc0ee",
"children":[
"Inherited Thrombophilias"
]
},
"children":[
{
"type":"p",
"hlId":"8e4f41",
"children":[
"Inherited thrombophilias typically affect components of the coagulation cascade (see ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f26",
"wrapId":"1",
"children":[
"Figure 26"
]
}
]
},
" in Bleeding Disorders) by causing the prothrombotic system to continue unsuppressed or by inhibiting clot lysis. All known inherited thrombophilias are autosomal dominant; therefore, most affected patients are heterozygous for the disorder. The two most common inherited thrombophilias are factor V Leiden (FVL) and prothrombin ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"G20210A"
]
},
" gene mutation. Antithrombin deficiency and protein C and S deficiencies are less common but are more significant risk factors for VTE."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_hm_f26"
]
},
{
"type":"p",
"hlId":"a27300",
"children":[
"Failure to identify a thrombophilia through laboratory testing does not mean one does not exist. Studies have shown that even without an identified inherited disorder, a family history of thrombosis remains an independent risk factor for VTE."
]
},
{
"type":"p",
"hlId":"01a8bc",
"children":[
"Although identification of the inherited thrombophilias has advanced the understanding of VTE pathophysiology, it has little influence on clinical management. The acute management of patients with VTE does not differ based on the presence of an inherited thrombophilia. Management duration is typically determined by whether the VTE event was provoked by a reversible or self-limited insult. Even if an inherited thrombophilia is found in a patient with VTE, asymptomatic family members should not undergo thrombophilia testing."
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_2_1",
"title":{
"__html":"Factor V Leiden"
},
"titleNode":{
"type":"section-title",
"hlId":"603c88",
"children":[
"Factor V Leiden"
]
},
"children":[
{
"type":"p",
"hlId":"3d3ac2",
"children":[
"FVL is the most common inherited thrombophilia type. Activated factor V combines with factor X to produce thrombin, which leads to clot formation. This process is regulated by activated protein C, which inactivates factor V to stop the process of ongoing clot formation. In FVL, mutated factor V is resistant to cleavage by activated protein C, leading to a prothrombotic state. Heterozygous FVL is most common in patients of European ancestry, affecting up to 5% of this population. Although persons who are heterozygous have a fourfold to eightfold increased risk for developing a first VTE compared with otherwise healthy persons, most remain asymptomatic, and recent studies suggest that these patients are not at higher risk for recurrent thrombosis compared with healthy persons. FVL and the other inherited thrombophilias do not appear to be associated with arterial thrombosis. FVL genetic testing or activated protein C resistance testing can be used to diagnose this condition."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_2_2",
"title":{
"__html":"Prothrombin <i>G20210A</i> Gene Mutation"
},
"titleNode":{
"type":"section-title",
"hlId":"40bc57",
"children":[
"Prothrombin ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"G20210A"
]
},
" Gene Mutation"
]
},
"children":[
{
"type":"p",
"hlId":"1f82c2",
"children":[
"The prothrombin ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"G20210A"
]
},
" gene mutation causes increased production of prothrombin (factor II) through a guanine to adenine substitution at nucleotide 20210. It affects up to 3% of patients from Europe but is rare in those from elsewhere. Persons with this mutation are at a twofold to fourfold increased risk for developing a first VTE, although most patients with this mutation do not experience VTE events. Data are unclear regarding risks with the homozygous state, which is rare."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_2_3",
"title":{
"__html":"Antithrombin Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"04aeea",
"children":[
"Antithrombin Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"1fa74e",
"children":[
"Antithrombin III (ATIII) and proteins C and S serve as natural anticoagulants in the body. Mutations leading to loss of function or production of these components increase the risk of VTE."
]
},
{
"type":"p",
"hlId":"5c5578",
"children":[
"ATIII deficiency, although rare, with a prevalence of 1 in 3000 to 5000 persons, is a more significant thrombophilic risk factor than FVL or prothrombin ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"G20210A"
]
},
" gene mutation. The main role of ATIII is to inhibit thrombin and activated factors IX and X (IXa and Xa). Thrombosis occurs in 30% of patients with heterozygous ATIII deficiency by age 30 years and in 65% by age 50 years. The thrombosis risk is particularly high during pregnancy, leading to VTE-related pregnancy loss and pregnancy morbidity. Acquired ATIII deficiency is much more common than congenital deficiency ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t28",
"wrapId":"2",
"children":[
"Table 28"
]
}
]
},
")"
]
},
". Repeat testing is typically required to determine whether the deficiency is persistent."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_hm_t28"
]
},
{
"type":"p",
"hlId":"519049",
"children":[
"For patients in whom heparin is initiated and titration to a therapeutic range is difficult, ATIII deficiency should be considered because heparin requires ATIII to be effective. ATIII concentrate can be used to treat this condition."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_2_4",
"title":{
"__html":"Protein C Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"1e38fa",
"children":[
"Protein C Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"258526",
"children":[
"Protein C is a vitamin K–dependent protein that degrades activated factors V and VIII. Heterozygous protein C deficiency has a prevalence of 2 to 5 per 1000 persons and is often associated with pregnancy morbidity or a thrombotic event before age 50 years, with a strong family history of thrombosis. Patients can develop warfarin-induced skin necrosis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f27",
"wrapId":"3",
"children":[
"Figure 27"
]
}
]
},
")"
]
},
" because of rapid depletion of protein C, which proceeds faster than depletion of the coagulation factors. Homozygous deficiency is rare and causes neonatal purpura fulminans. If protein C deficiency is found, acquired causes should be ruled out (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t28",
"wrapId":"3",
"children":[
"Table 28"
]
}
]
},
")"
]
},
". Patients should not be tested during acute VTE events or while receiving warfarin. Protein C functional testing can be ordered to evaluate for deficiency; confirmatory testing is often necessary."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_hm_f27",
"mk19_b_hm_t28"
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_2_5",
"title":{
"__html":"Protein S Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"0cd231",
"children":[
"Protein S Deficiency"
]
},
"children":[
{
"type":"p",
"hlId":"9b9f1c",
"children":[
"Protein S is a vitamin K–dependent protein that functions as a cofactor for protein C and degrades activated factors V and VIII. Deficiency is uncommon and bears many similarities to protein C deficiency. Patients who are heterozygous for protein S deficiency typically experience VTE at a younger age (<50 years). Protein S circulates in a free form and is bound to a complement-binding protein. Although case reports of functional protein S deficiency are rare, immunoassay of the free form is usually sufficient for diagnosis. Protein S deficiency is likely the most difficult hereditary thrombophilia to confirm because multiple laboratory assays are available, but cutoffs between normal and deficient are imprecise."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_2_6",
"title":{
"__html":"Other Inherited Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"fc6e9d",
"children":[
"Other Inherited Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"445aa6",
"children":[
"Methylene tetrahydrofolate reductase (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MTHFR"
]
},
") gene polymorphisms cause mild elevations in homocysteine levels, which are associated with a slightly increased risk of cardiovascular and thrombotic disease. The heterozygous mutation is common in those of European ancestry but may be a marker of thrombotic risk rather than a cause of thrombosis."
]
},
{
"type":"p",
"hlId":"242b7d",
"children":[
"Testing for the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MTHFR"
]
},
" mutation and measuring homocysteine levels, in addition to factor VIII levels and plasminogen activator inhibitor activity, should not be part of the standard thrombophilia evaluation, because clinical trials regarding their importance have been inconclusive and results do not influence management."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"caf7c6",
"children":[
"Although the risk of venous thromboembolism is increased in patients who are heterozygous for factor V Leiden or the prothrombin ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"G20210A"
]
},
" gene mutation, most patients are asymptomatic."
]
},
{
"type":"keypoint",
"hlId":"070421",
"children":[
"For patients in whom heparin is initiated and titration to a therapeutic range is difficult, antithrombin deficiency should be considered."
]
},
{
"type":"keypoint",
"hlId":"34d2e1",
"hvc":true,
"children":[
"Deficiencies of the vitamin K–dependent factors protein C and S are rare, and testing for these deficiencies should not be performed during an acute thrombotic event or anticoagulation with warfarin."
]
},
{
"type":"keypoint",
"hlId":"0b63de",
"hvc":true,
"children":[
"Testing for methylene tetrahydrofolate reductase, as well as measuring homocysteine levels, factor VIII levels, and plasminogen activator inhibitor activity should not be part of the standard thrombophilia evaluation because results do not influence management."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_3",
"title":{
"__html":"Acquired Thrombophilias"
},
"titleNode":{
"type":"section-title",
"hlId":"8b5bb9",
"children":[
"Acquired Thrombophilias"
]
},
"children":[
{
"type":"p",
"hlId":"d5669c",
"children":[
"VTE is more likely to occur in the setting of an acquired rather than an inherited thrombophilia. Many conditions predispose patients to the development of thrombosis."
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_3_1",
"title":{
"__html":"Surgery, Trauma, Hospitalization, and Immobility"
},
"titleNode":{
"type":"section-title",
"hlId":"93fe6b",
"children":[
"Surgery, Trauma, Hospitalization, and Immobility"
]
},
"children":[
{
"type":"p",
"hlId":"d18377",
"children":[
"Surgery, trauma, hospitalization, and immobilization are some of the most significant risk factors for VTE. VTE occurs frequently in medical and surgical patients; approximately half of all new VTEs are diagnosed during or within 3 months of a hospital stay or surgical procedure. If prophylaxis is not used, the risk of DVT in patients undergoing general surgery is 15% to 30%. The risk of DVT is approximately 60% after hip fracture surgery. Patients with cancer who undergo surgery and those undergoing orthopedic procedures, including knee arthroplasty, hip fracture repair, or hip replacement, are at particularly high risk. Nosocomial VTE risk is also increased for nonsurgical hospitalized patients, especially those who are immobilized, have acute neurologic illness, or are in the medical ICU. Decision support tools, including the Caprini score (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.mdcalc.com/caprini-score-venous-thromboembolism-2005",
"target":"_blank"
},
"children":[
"https://www.mdcalc.com/caprini-score-venous-thromboembolism-2005"
]
},
"), can help stratify nosocomial VTE risk and are most helpful in the perioperative setting."
]
},
{
"type":"p",
"hlId":"231a84",
"children":[
"Certain medical conditions, including inflammatory conditions, nephrotic syndrome, and inflammatory bowel disease, are associated with increased thrombotic risk. Obesity is also associated with increased thrombotic risk."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_3_2",
"title":{
"__html":"Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"746354",
"children":[
"Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"125847",
"children":[
"Cancer is diagnosed in 10% of patients within 1 year of an unprovoked VTE occurrence. Cancer of the ovary, pancreas, and liver are most frequently found. The only randomized controlled clinical trial that compared routine age- and sex-indicated screening with extensive malignancy screening showed no survival benefit with extensive malignancy screening."
]
},
{
"type":"p",
"hlId":"7c7f5c",
"children":[
"Thrombosis remains a leading cause of death in patients with cancer and is a significant source of morbidity. Increased thrombotic risk has been associated with numerous malignancies. Thromboprophylaxis is not recommended in all outpatients with cancer, but prophylaxis with apixaban, rivaroxaban, or low-molecular-weight heparin (LMWH) can be given to patients at the highest risk for thrombosis (defined by a Khorana score of 2 or greater; ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t29",
"wrapId":"4",
"children":[
"Table 29"
]
}
]
},
")"
]
},
" before starting a new systemic chemotherapy regimen after careful consideration and discussion of bleeding risks and benefits. In some patients with multiple myeloma, aspirin or fixed low-dose warfarin may be considered for thromboprophylaxis."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_hm_t29"
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_3_3",
"title":{
"__html":"Medication"
},
"titleNode":{
"type":"section-title",
"hlId":"353bd6",
"children":[
"Medication"
]
},
"children":[
{
"type":"p",
"hlId":"c7b91b",
"children":[
"Hormones used in contraceptives and in the treatment of menopause increase the risk of VTE. The risk in women using oral contraceptives is increased approximately threefold, but the absolute number of patients affected remains small. VTE risk is highest with combined oral contraceptives containing both estrogen and progesterone. Regardless of the type of contraceptive, VTE risk tends to be greater in women who have obesity and in those 39 years or older. Women with a previous VTE event should avoid combined oral contraceptives and low-dose estrogen replacement therapy when possible; however, experts do not recommend routine thrombophilia screening before beginning contraceptive use. VTE risk is increased by approximately twofold in menopausal women taking conjugated estrogen-medroxyprogesterone hormone replacement therapy, but the absolute risk remains small. The VTE risk appears lower in menopausal women taking only estrogen and in those using transdermal hormone replacement."
]
},
{
"type":"p",
"hlId":"0dafab",
"children":[
"The antiestrogen, tamoxifen, also increases VTE risk in women with estrogen receptor–positive breast cancer; this risk increases further, approximately three times baseline, in women receiving tamoxifen with systemic chemotherapy. The risk for VTE with aromatase inhibitors, such as anastrozole, is lower than with tamoxifen."
]
},
{
"type":"p",
"hlId":"561161",
"children":[
"Patients with multiple myeloma receiving an immunomodulatory agent, such as lenalidomide or pomalidomide, have a significant risk for VTE that warrants prophylaxis with aspirin, LMWH, fixed-dose warfarin, or a factor Xa inhibitor, depending on the patient's risk profile. The vascular endothelial growth factor inhibitor bevacizumab and newer multitargeted tyrosine kinase inhibitors, such as sunitinib and sorafenib, also increase VTE risk."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_3_4",
"title":{
"__html":"Antiphospholipid Antibody Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"fd361b",
"children":[
"Antiphospholipid Antibody Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"640918",
"children":[
"Antiphospholipid antibody syndrome (APLAS) is an autoimmune disorder associated with venous and arterial thrombosis, as well as increased risk of fetal demise during pregnancy."
]
},
{
"type":"p",
"hlId":"d22cf8",
"children":[
"APLAS evaluation includes the anticardiolipin antibodies, anti–β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-glycoprotein antibodies, and lupus anticoagulant. The diagnosis of APLAS is based on the clinical criteria of thromboembolism or pregnancy morbidity and laboratory findings of medium- or high-titer antiphospholipid antibodies on two or more occasions at least 12 weeks apart ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t30",
"wrapId":"5",
"children":[
"Table 30"
]
}
]
},
")"
]
},
". A clue to the presence of the lupus anticoagulant is activated partial thromboplastin time (aPTT) prolongation."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_hm_t30"
]
},
{
"type":"p",
"hlId":"80e997",
"children":[
"Typically, patients diagnosed with APLAS require long-term anticoagulation because of the risk of recurrent thrombosis. In patients with confirmed APLAS being managed with anticoagulant therapy, the 2021 CHEST guideline suggests adjusted-dose vitamin K antagonist (VKA; target INR 2.5) over direct oral anticoagulant (DOAC) therapy during the treatment phase. VKA therapy initiation should include an overlapping period of parenteral anticoagulation."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_2_3_5",
"title":{
"__html":"Other Acquired Thrombophilic Conditions"
},
"titleNode":{
"type":"section-title",
"hlId":"de860b",
"children":[
"Other Acquired Thrombophilic Conditions"
]
},
"children":[
{
"type":"p",
"hlId":"061fb6",
"children":[
"The myeloproliferative neoplasms have been found to confer an increased risk of thrombosis, including PE, DVT, portal vein thrombosis, and Budd-Chiari syndrome (hepatic venous outflow obstruction) (see ",
{
"type":"cross-reference",
"target":"mk19_a_gi_s6_15_2",
"children":[
"MKSAP 19 Gastroenterology and Hepatology"
]
},
"). Evidence of a myeloproliferative neoplasm is discovered in approximately 50% of patients with Budd-Chiari syndrome, even when the complete blood count is normal. In the setting of splanchnic vein thrombosis (portal vein, splenic vein, hepatic vein, or mesenteric vein thrombosis), evaluation for evidence of a myeloproliferative neoplasm should be considered, including evaluation for the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" tyrosine kinase mutation."
]
},
{
"type":"p",
"hlId":"ea5731",
"children":[
"Paroxysmal nocturnal hemoglobinuria is another acquired stem cell disorder associated with hemolytic anemia, bone marrow failure, and thrombosis (see ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s4_3_1_5",
"children":[
"Erythrocyte Disorders"
]
},
")."
]
},
{
"type":"p",
"hlId":"b14b1d",
"children":[
"A previous VTE is one of the most significant predictors of a subsequent VTE, regardless of whether an additional inherited or acquired thrombophilic risk factor is identified."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"9bd939",
"children":[
"Approximately half of all new venous thromboembolisms are diagnosed during or within 3 months of a hospital stay or surgical procedure."
]
},
{
"type":"keypoint",
"hlId":"9bfc32",
"children":[
"Patients with cancer undergoing extensive surgery or patients undergoing knee arthroplasty, hip fracture repair, or hip replacement surgery are at especially high risk for postoperative venous thromboembolism."
]
},
{
"type":"keypoint",
"hlId":"1965f1",
"children":[
"The diagnosis of antiphospholipid antibody syndrome is based on the clinical criteria of thromboembolism or pregnancy morbidity and laboratory findings of medium- or high-titer antiphospholipid antibodies present on two or more occasions at least 12 weeks apart."
]
},
{
"type":"keypoint",
"hlId":"7bf296",
"children":[
"Evidence of a myeloproliferative neoplasm is found in approximately 50% of patients with Budd-Chiari syndrome, and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
" tyrosine kinase mutation testing should be performed even if blood counts are normal."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_3",
"title":{
"__html":"Deep Venous Thrombosis and Pulmonary Embolism"
},
"titleNode":{
"type":"section-title",
"hlId":"c4d506",
"children":[
"Deep Venous Thrombosis and Pulmonary Embolism"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s9_3_1",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"b691a8",
"children":[
"All hospitalized patients should be assessed for the risk of developing a VTE and treated with appropriate prophylaxis (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s3_3",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
") because VTE is a major preventable cause of hospital morbidity and mortality. Generally, unless a clear contraindication to prophylaxis exists, pharmacologic treatment is preferred to mechanical prophylaxis. No additional benefit exists to using pneumatic compression devices with pharmacologic prophylaxis. Patients with cancer or stroke history, or those in the ICU, have a particularly high risk for VTE. Despite the well-recognized risks of VTE, the rate of appropriate prophylaxis remains low in hospitalized patients. Most patients do not require continued pharmacologic VTE prevention after discharge. However, patients with cancer or other high-risk features who are undergoing major surgical procedures, patients undergoing knee arthroplasty, and those with hip fracture repair or hip replacement require extended VTE prophylaxis after discharge."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_3_2",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"10f4a4",
"children":[
"VTE causes significant morbidity and requires efficient evaluation and diagnosis. Previous VTE, positive family history, and other thrombophilia risk factors, especially cancer, should be assessed, as well as other potential causes of leg or respiratory symptoms. The typical clinical presentation of DVT involves unilateral swelling, pain, warmth, and erythema of the extremity. Patients with PE may present with chest pain, dyspnea, and tachypnea; less common symptoms may include cough, fever, cyanosis, syncope, or shock."
]
},
{
"type":"p",
"hlId":"68ed5b",
"children":[
"CT angiography has significantly improved the accuracy of PE evaluation, generally replacing the less specific ventilation-perfusion scan and avoiding the need for more invasive pulmonary arteriography. However, the overuse of CT angiography and D-dimer measurement in outpatients at low risk for PE needlessly exposes patients to additional radiation and expense. For patients with symptoms suspicious for an acute VTE, validated prediction rules have been developed that use D-dimer testing to help effectively evaluate patients. The Wells criteria for diagnosis of DVT ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t31",
"wrapId":"6",
"children":[
"Table 31"
]
}
]
},
")"
]
},
" and PE ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t32",
"wrapId":"6",
"children":[
"Table 32"
]
}
]
},
")"
]
},
" are well-studied tools. A subset of patients at very low risk may be identified using the Pulmonary Embolism Rule-Out Criteria (PERC) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t33",
"wrapId":"6",
"children":[
"Table 33"
]
}
]
},
")"
]
},
". If the PERC score is zero, no D-dimer testing or CT angiography should be performed (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_hm_v01",
"wrapId":"6",
"children":[
"Video 1"
]
}
]
},
"). A meta-analysis of 12 studies found that if the PERC were applied, only 0.3% of PEs would have been missed, and 22% of D-dimer testing would have been safely avoided."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_hm_t31",
"mk19_b_hm_t32",
"mk19_b_hm_t33",
"mk19_b_hm_v01"
]
},
{
"type":"p",
"hlId":"d8ffe3",
"children":[
"In patients at low risk with a PERC score greater than zero, D-dimer testing should be pursued. If the result is negative, no imaging is warranted. If the result is positive, further evaluation is merited. If a patient has a moderate or high pretest probability, imaging studies are indicated. D-dimer testing may be considered in patients with moderate pretest probability (~20%) but should not be pursued in those with high pretest probability because results would not change the need for imaging."
]
},
{
"type":"p",
"hlId":"dbc6a2",
"children":[
"In patients with kidney disease or in whom intravenous contrast is contraindicated, a ventilation/perfusion lung scan can be pursued. A normal ventilation/perfusion scan effectively rules out PE. A high probability study result in a patient with a high likelihood of disease has a strong positive predictive value. The sensitivity and specificity of low probability or intermediate probability study results may not be accurate enough to establish or rule out PE. MRI avoids ionizing radiation and can visualize intraluminal filling defects in the pulmonary vasculature, but not as well as CT. New MRI techniques are being evaluated that may enhance its role in VTE diagnosis. Presently, CT is still considered the diagnostic standard. Duplex ultrasonography (B-mode imaging with Doppler assessment of blood flow) is the imaging modality of choice for suspected DVT, although in recent years growing evidence shows that point-of-care compression ultrasonography performed by hospital medicine providers may potentially eliminate the need for duplex ultrasonography ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f28",
"wrapId":"7",
"children":[
"Figure 28"
]
}
]
}
]
},
", ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_hm_v02",
"wrapId":"7",
"children":[
"Video 2"
]
}
]
},
"). Lower extremity DVT is considered proximal if the popliteal, femoral, or iliac veins are involved and is considered distal if only the calf veins (peroneal, posterior, and anterior tibial) are involved. The American Society of Hematology (ASH) recommends a strategy of D-dimer measurement to exclude DVT in a population with low probability of DVT (≤10%) followed by proximal lower extremity ultrasonography or whole-leg ultrasonography for patients requiring additional testing. For patients with a moderate probability of DVT (~25%), the ASH guideline recommends beginning the evaluation with whole-leg or proximal lower extremity ultrasonography without D-dimer testing. No additional testing is recommended if the whole-leg ultrasound is negative. For patients with high pretest probability, duplex ultrasonography is also recommended. In patients with moderate or high probability of DVT, a second proximal leg ultrasonography should be performed 1 week later if no alternative diagnosis for the leg symptoms is identified."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_hm_f28",
"mk19_b_hm_v02"
]
},
{
"type":"p",
"hlId":"146c07",
"children":[
"Patients with a confirmed PE do not require routine duplex imaging of the lower extremities, and patients with acute DVT in the absence of respiratory symptoms do not require CT angiography. Patients with established PE can undergo echocardiography (right ventricular strain and pulmonary hypertension indicating a more massive PE) or testing of serum troponin and B-type natriuretic peptide for risk stratification."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c91228",
"hvc":true,
"children":[
"Patients with a Pulmonary Embolism Rule-Out Criteria score of zero do not require further testing with D-dimer or imaging."
]
},
{
"type":"keypoint",
"hlId":"f57dec",
"hvc":true,
"children":[
"Patients with a low-probability Wells criteria score for DVT or PE should undergo D-dimer testing; if the results are normal, no further imaging is necessary."
]
},
{
"type":"keypoint",
"hlId":"31fbaf",
"children":[
"Patients with a moderate- or high-probability Wells criteria score do not require D-dimer testing but should undergo duplex imaging of the lower extremities for symptoms suggesting deep venous thrombosis or CT angiography for symptoms suggesting pulmonary embolism."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_3_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"5fe90f",
"children":[
"Most patients with DVT can be efficiently and safely diagnosed and treated without hospitalization. A subset of patients with PE with an excellent prognosis can also avoid inpatient care. The original Pulmonary Embolism Severity Index (PESI) is a validated prediction tool for clinical severity and outcomes of patients with PE. Using 11 clinical criteria, patients with PE are categorized into classes I through V, with class I and class II considered low risk for adverse outcomes. In a multicenter, prospective, open-label, randomized trial of patients with low-risk PE as determined by the PESI score, no difference was found between outpatient and inpatient management in recurrent VTE, major bleeding, or 90-day mortality. A simplified version of the PESI defines patients with PE who are 80 years or younger without significant comorbidity, who have a pulse rate less than 110/min, systolic blood pressure of 100 mm Hg or greater, and oxygen saturation of 90% or greater breathing ambient air as low risk for adverse outcomes ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t34",
"wrapId":"8",
"children":[
"Table 34"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_hm_t34"
]
},
{
"type":"p",
"hlId":"07aa0d",
"children":[
"For most patients, anticoagulation is the primary treatment for VTE. Anticoagulant options for acute VTE include a DOAC, unfractionated heparin (UFH), LMWH, fondaparinux, or warfarin; CHEST guidelines recommend a DOAC over VKAs. Patients taking LMWH or fondaparinux must learn injection techniques. Warfarin, dabigatran, and edoxaban require initial concomitant parenteral heparin therapy. Apixaban and rivaroxaban are effective as monotherapy. For patients receiving anticoagulation therapy for VTE who experience major bleeding, the ASH suggests restarting oral anticoagulation therapy within 90 days. Patients who require hospitalization should avoid initial treatment with UFH because of its unpredictable bioavailability compared with LMWH; however, because of its short half-life, UFH may be preferred in patients who are unstable and who may need emergent surgery or thrombolytic therapy."
]
},
{
"type":"p",
"hlId":"ee1b44",
"children":[
"According to the 2020 ASH VTE guideline, thrombolytic therapy is reasonable in select younger patients or in those at high risk for decompensation because of concomitant cardiopulmonary disease who have submassive PE and a low bleeding risk. For acute DVT, thrombolysis is indicated in patients with massive thrombus leading to impaired venous drainage, severe edema, and acute limb ischemia. The 2021 CHEST guidelines recommend against thrombolytic therapy in most patients with acute PE not associated with hypotension and suggests anticoagulant therapy alone over interventional therapy for acute DVT of the leg."
]
},
{
"type":"p",
"hlId":"76265d",
"children":[
"Therapy duration varies based on the clinical scenario ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t35",
"wrapId":"9",
"children":[
"Table 35"
]
}
]
},
")"
]
},
". In provoked thrombosis with reversible risk factors, 3 to 6 months of anticoagulation is adequate. Extended therapy should be considered in patients with irreversible risk factors for recurrent VTE. After initial full-dose anticoagulation, reduced dosing of apixaban or rivaroxaban could also be considered in patients with unprovoked VTE with low bleeding risk. If extended therapy is chosen, the risks, benefits, and choice of anticoagulant should be re-evaluated yearly. In patients with unprovoked VTE in whom anticoagulation is discontinued, aspirin is associated with an approximately 30% to 40% risk reduction in recurrent VTE compared with placebo. The 2021 CHEST guidelines suggest aspirin in patients with an unprovoked proximal DVT or PE who are stopping anticoagulation therapy; however, continued anticoagulation is preferred."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_hm_t35"
]
},
{
"type":"p",
"hlId":"6ca9ea",
"children":[
"In patients with malignancy and VTE, the ASH 2020 guideline recommends initial anticoagulation with apixaban, rivaroxaban, or LMWH. If heparin is selected as initial anticoagulation, LMWH is preferred to UFH in the absence of severe kidney disease. For the initial 3 to 6 months of anticoagulation, apixaban, rivaroxaban, or edoxaban are preferred to LMWH or warfarin. The 2021 CHEST guidelines recommend apixaban, edoxaban, and rivaroxaban over LMWH for the initiation and treatment phases of therapy. Apixaban or LMWH may be the preferred option in patients with luminal gastrointestinal malignancies because of a lower risk of bleeding. Anticoagulation should be extended beyond 6 months in select patients with active cancer, such as in those with metastatic disease or those receiving chemotherapy."
]
},
{
"type":"p",
"hlId":"b1e50a",
"children":[
"Inferior vena cava (IVC) filters have been used to prevent death from PE but are known to increase the risk of DVT. The ACCP and ASH recommend against IVC filters for patients treated with anticoagulants but support the use of IVC filters in those with an acute proximal DVT or an acute PE with a contraindication to anticoagulation. If an IVC filter is placed, a temporary filter should be used and removed as soon as the indication for the filter has resolved."
]
},
{
"type":"p",
"hlId":"1b8201",
"children":[
"Patients with asymptomatic or mildly symptomatic distal DVTs do not usually require anticoagulation (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t35",
"wrapId":"10",
"children":[
"Table 35"
]
}
]
},
")"
]
},
". According to ACCP guidelines, anticoagulation similar to that for proximal DVT is suggested in patients with moderate to severe symptoms or those with certain risk factors for extension, including a positive D-dimer test result, extensive thrombosis or proximity to proximal veins, no reversible provoking factor for DVT, active cancer, history of VTE, and inpatient status."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_hm_t35"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"6cf427",
"hvc":true,
"children":[
"Most patients with deep venous thrombosis and those with pulmonary embolism who have a good prognosis (defined as age <80 years, no significant comorbidity, and stable vital signs) can be safely managed without hospitalization."
]
},
{
"type":"keypoint",
"hlId":"3455ff",
"children":[
"If patients with deep venous thrombosis or pulmonary embolism require hospitalization, they should be treated initially with low-molecular-weight heparin, fondaparinux, or direct oral anticoagulants (apixaban or rivaroxaban) instead of unfractionated heparin, unless they are unstable and at risk for requiring emergent surgery or thrombolytic therapy."
]
},
{
"type":"keypoint",
"hlId":"f1bcae",
"children":[
"In patients with a provoked thrombosis with reversible risk factors, 3 to 6 months of anticoagulation is adequate, but in patients at low bleeding risk with unprovoked VTE or with irreversible risk factors, extended therapy should be considered."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_3_4",
"title":{
"__html":"Long-term Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"408aba",
"children":[
"Long-term Complications"
]
},
"children":[
{
"type":"p",
"hlId":"7f0c82",
"children":[
"Patients with DVT or PE can develop long-term complications affecting function and quality of life. Approximately 25% to 40% of patients with symptomatic DVT develop aspects of postthrombotic syndrome and chronic venous insufficiency, which often develop within 2 years of VTE. Symptoms of postthrombotic syndrome include pain, heaviness, swelling, stasis dermatitis, and ulceration in the affected limb. Treatment includes leg exercises, avoiding dependent positions for lengthy periods, and using compression stockings. Emollients and a low-moderate potency topical glucocorticoid may be used for stasis dermatitis (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s10_3_7",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
")."
]
},
{
"type":"p",
"hlId":"3c60f9",
"children":[
"Patients with PE can also develop chronic thromboembolic pulmonary hypertension (see ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s6_3",
"children":[
"MKSAP 19 Pulmonary and Critical Care Medicine"
]
},
"), cardiopulmonary dysfunction, or decreased exercise tolerance."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_4",
"title":{
"__html":"Other Sites of Thrombosis"
},
"titleNode":{
"type":"section-title",
"hlId":"9bd95d",
"children":[
"Other Sites of Thrombosis"
]
},
"children":[
{
"type":"p",
"hlId":"3879f3",
"children":[
"Additional sites of thromboses, such as splanchnic, cerebral, and retinal vein thromboses are discussed elsewhere (see MKSAP 19 Gastroenterology, Neurology, and General Internal Medicine, respectively)."
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_4_1",
"title":{
"__html":"Superficial Vein Thrombosis and Thrombophlebitis"
},
"titleNode":{
"type":"section-title",
"hlId":"87669a",
"children":[
"Superficial Vein Thrombosis and Thrombophlebitis"
]
},
"children":[
{
"type":"p",
"hlId":"604789",
"children":[
"Superficial thrombophlebitis describes thrombus and associated inflammation in a vein located near the skin's surface; it is a common inflammatory-thrombotic disorder that does not usually cause significant morbidity or progress to PE. It typically occurs in the setting of cancer or an underlying hypercoagulable state. Cannulated veins of the hands and arms can thrombose after infusions or intravenous catheter placement; this condition does not require anticoagulant therapy (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t35",
"wrapId":"11",
"children":[
"Table 35"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_hm_t35"
]
},
{
"type":"p",
"hlId":"8a7aa6",
"children":[
"Superficial vein thrombosis (SVT) often affects the lower extremities and is thought to account for 10% of lower extremity thromboses. When affecting the great saphenous vein (also referred to as the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"greater"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"long saphenous vein"
]
},
"), SVT may progress into the deep venous system. In patients with SVT who are treated with anticoagulation, the 2021 CHEST guidelines suggest low dose fondaparinux over other anticoagulant treatment regimens as safe and effective in preventing PE; therefore, anticoagulation may be indicated in select patients (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t35",
"wrapId":"12",
"children":[
"Table 35"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_hm_t35"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"140abd",
"children":[
"Patients with lower extremity superficial vein thrombosis managed conservatively with warm compresses, analgesics, and NSAIDs require follow-up evaluation after 1 week to determine whether symptoms have resolved; duplex imaging is indicated for symptoms that persist or worsen."
]
},
{
"type":"keypoint",
"hlId":"ee4157",
"children":[
"In patients with lower extremity superficial vein thrombosis of at least 5 cm in length, close to the deep venous system, or with other thrombophilic risk factors, including cancer or previous venous thromboembolism, anticoagulation is recommended."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_4_2",
"title":{
"__html":"Unexplained Arterial Thrombosis"
},
"titleNode":{
"type":"section-title",
"hlId":"33ac61",
"children":[
"Unexplained Arterial Thrombosis"
]
},
"children":[
{
"type":"p",
"hlId":"d9ea20",
"children":[
"With few exceptions, such as APLAS or myeloproliferative disorders, thrombophilias do not play a significant role in arterial thrombosis. The primary causes of arterial thrombosis are arteriosclerosis and atrial fibrillation with systemic arterial embolism. Patients with arterial thrombosis resulting from arteriosclerosis are typically treated with antiplatelet therapy. It is unknown whether patients with arterial clots in whom a strong thrombophilia is found are more effectively treated with antiplatelet therapy or anticoagulants."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"673a24",
"children":[
"Patients with arterial thrombosis resulting from arteriosclerosis are typically treated with antiplatelet therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_4_3",
"title":{
"__html":"Upper Extremity Deep Venous Thrombosis"
},
"titleNode":{
"type":"section-title",
"hlId":"6a7739",
"children":[
"Upper Extremity Deep Venous Thrombosis"
]
},
"children":[
{
"type":"p",
"hlId":"05f969",
"children":[
"Upper extremity DVT accounts for 10% of all DVT occurrences, most of which (approximately two thirds) are associated with central venous catheter use or malignancy. Treatment consists of anticoagulation for 3 months or at least the duration that the catheter remains in place. The ASH recommends against catheter removal because of thrombosis."
]
},
{
"type":"p",
"hlId":"08b45c",
"children":[
"Primary upper extremity DVT is uncommon and usually caused by anatomic abnormalities of the thoracic outlet system leading to axillosubclavian compression and thrombosis (venous thoracic outlet syndrome). Patients are usually young, and thrombus occurs with strenuous upper extremity activity. Expert recommendations vary regarding the use of thrombolysis or thoracic outlet decompression surgery in addition to anticoagulation. ACCP guidelines recommend that treatment of primary and secondary upper extremity DVT follow similar guidelines as lower extremity DVT."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"9bb6e0",
"children":[
"Provoked upper extremity deep venous thrombosis (DVT) should be managed with 3 months of anticoagulation; however, in patients with catheter-associated DVT, anticoagulation should continue for as long as the catheter remains in place."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_5",
"title":{
"__html":"Anticoagulants"
},
"titleNode":{
"type":"section-title",
"hlId":"c6b422",
"children":[
"Anticoagulants"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s9_5_1",
"title":{
"__html":"Parenteral"
},
"titleNode":{
"type":"section-title",
"hlId":"a807f0",
"children":[
"Parenteral"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s9_5_1_1",
"title":{
"__html":"Unfractionated Heparin"
},
"titleNode":{
"type":"section-title",
"hlId":"c9ee31",
"children":[
"Unfractionated Heparin"
]
},
"children":[
{
"type":"p",
"hlId":"d890c2",
"children":[
"UFH works by binding to antithrombin, potentiating its action, resulting in inactivation of thrombin and factor Xa."
]
},
{
"type":"p",
"hlId":"8e1ce9",
"children":[
"The aPTT is used in monitoring heparin therapy. In the setting of lupus anticoagulant (which prolongs the aPTT), heparin resistance, or markedly elevated factor VIII, anti–factor Xa monitoring can be used. Although ideal dosing is controversial, a weight-based nomogram is usually used, and most hospitals follow a specific dosing algorithm. Typically, an initial bolus dose of 80 to 100 U/kg is given. UFH is available in intravenous and subcutaneous preparations, although the intravenous form is typically used for treatment of VTE."
]
},
{
"type":"p",
"hlId":"34d37b",
"children":[
"The rate of heparin-associated major bleeding is approximately 3%. Failure to follow a dosage adjustment algorithm is associated with increased bleeding risk. When major bleeding occurs, protamine sulfate can be administered to reverse anticoagulation, using a dose of 1 mg of protamine per 100 units of heparin administered in the previous 2 hours. Protamine adverse effects include allergic reactions, hypotension, bradycardia, and respiratory toxicity."
]
},
{
"type":"p",
"hlId":"1bbb74",
"children":[
"Although weight-based nomograms and specific algorithms for adjusting dose based on aPTT results have enhanced the safety and efficacy of UFH, variations in bioavailability and potential delay in arriving at a therapeutic dose are still more likely than with LMWH. UFH should therefore be reserved for patients in whom LMWH is contraindicated or in those who require anticoagulation that can be stopped quickly, generally in anticipation of an invasive procedure or surgery."
]
},
{
"type":"p",
"hlId":"89e5b6",
"children":[
"Heparin-induced thrombocytopenia is a severe complication of heparin that can result in a catastrophic thrombotic event (see ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s6_3_2_3",
"children":[
"Platelet Disorders"
]
},
")."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8925d9",
"children":[
"A weight-based nomogram is usually used to determine the initial dose of unfractionated heparin, and algorithms are used to calculate subsequent dose modifications based on the activated partial thromboplastin time."
]
},
{
"type":"keypoint",
"hlId":"aa33ff",
"children":[
"Protamine sulfate can be administered to reverse the anticoagulant effects of unfractionated heparin."
]
},
{
"type":"keypoint",
"hlId":"235870",
"children":[
"Variations in bioavailability of unfractionated heparin lead to an increased likelihood of delay in achieving a steady-state therapeutic dose compared with treatment with low-molecular-weight heparin."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_5_1_2",
"title":{
"__html":"Low-Molecular-Weight Heparin"
},
"titleNode":{
"type":"section-title",
"hlId":"326683",
"children":[
"Low-Molecular-Weight Heparin"
]
},
"children":[
{
"type":"p",
"hlId":"7eb3e9",
"children":[
"LMWH is derived from UFH through a chemical depolymerization producing fragments that are one third the size of heparin."
]
},
{
"type":"p",
"hlId":"e59b86",
"children":[
"LMWH does not affect the aPTT because the smaller fragment size does not bind as readily to thrombin but retains the ability to inactivate factor Xa. It is usually administered in weight-adjusted doses. Dosing is more predictable, and laboratory testing is generally unnecessary. LMWH is cleared through the kidney, and the biological half-life is increased in patients with kidney disease. For patients with kidney dysfunction (creatinine clearance <30 mL/min) receiving LMWH therapy, the ASH suggests against using anti–factor Xa concentration monitoring to guide LMWH dose adjustment; instead, the organization considers using doses adjusted for kidney function as recommended in product labeling or switching to an alternative anticoagulant. In patients with obesity, dosing is based on actual body weight."
]
},
{
"type":"p",
"hlId":"a5a811",
"children":[
"LMWH is preferred to UFH. In a meta-analysis of DVT treatment, LMWH was associated with less major bleeding, decreased mortality, and decreased thrombotic recurrence compared with UFH."
]
},
{
"type":"p",
"hlId":"042e2f",
"children":[
"Protamine does not fully reverse the anti-Xa effect of LMWH but provides some benefit in restoring hemostasis and is recommended for life-threatening bleeding. It should be given at a dose of 1 mg of protamine per 1 mg of LMWH."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"a6de99",
"children":[
"Low-molecular-weight heparin typically does not require laboratory monitoring and is associated with less bleeding, decreased recurrent thrombosis, and improved mortality compared with unfractionated heparin."
]
},
{
"type":"keypoint",
"hlId":"85189c",
"children":[
"Patients with severe obesity or creatinine clearance less than 30 mL/min who are treated with low-molecular-weight heparin do not require anti–factor Xa level monitoring; doses should be adjusted based on kidney function or actual body weight."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_5_1_3",
"title":{
"__html":"Fondaparinux"
},
"titleNode":{
"type":"section-title",
"hlId":"bade34",
"children":[
"Fondaparinux"
]
},
"children":[
{
"type":"p",
"hlId":"c071eb",
"children":[
"In a clinical trial, fondaparinux, dose adjusted based on patients' weights, was noninferior to enoxaparin with respect to the primary endpoint of recurrent VTE at 3 months (3.9% vs. 4.1%). Fondaparinux is cleared through the kidney and should be avoided in patients with creatinine clearance less than 30 mL/min. As with LMWH or UFH, treatment with fondaparinux and warfarin should overlap for 5 days."
]
},
{
"type":"p",
"hlId":"e1bbbb",
"children":[
"Fondaparinux has no reversal agent. Caution should be used in patients at risk for bleeding because the half-life is 17 hours. Prothrombin complex concentrates (PCCs) and fresh frozen plasma have been administered with positive outcomes in patients experiencing bleeding."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"949b85",
"children":[
"Because fondaparinux is cleared through the kidney, it should be avoided in patients with creatinine clearance less than 30 mL/min."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_5_2",
"title":{
"__html":"Oral"
},
"titleNode":{
"type":"section-title",
"hlId":"1dfec3",
"children":[
"Oral"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s9_5_2_1",
"title":{
"__html":"Warfarin"
},
"titleNode":{
"type":"section-title",
"hlId":"00fb95",
"children":[
"Warfarin"
]
},
"children":[
{
"type":"p",
"hlId":"33a673",
"children":[
"Warfarin is a vitamin K antagonist (VKA). It inhibits vitamin K epoxide reductase, which leads to inhibition of γ-carboxylation of precursor coagulation factors II, VII, IX, and X and proteins C and S. Laboratory monitoring involves the prothrombin time and INR."
]
},
{
"type":"p",
"hlId":"40ea70",
"children":[
"Because warfarin lowers protein C levels before inducing its anticoagulant effect, it can initially cause a prothrombotic state. For this reason, when warfarin is used to treat acute VTE, it should be administered initially with a parenteral anticoagulant (e.g., UFH or LMWH). The parenteral agent should be given for at least 5 days and continued until the INR is 2 or greater for at least 24 hours."
]
},
{
"type":"p",
"hlId":"454cf1",
"children":[
"Although DOACs have changed the landscape of treatment for patients with VTE, warfarin remains a reasonable anticoagulant for some patients, including those with kidney disease, morbid obesity, a mechanical heart valve, or high-risk APLAS—conditions for which alternate oral anticoagulants are not routinely used."
]
},
{
"type":"p",
"hlId":"7f9ba9",
"children":[
"Patients must have access to continued outpatient INR monitoring. Common reasons for fluctuations in INR include changes in vitamin K intake, medications, and nonadherence. Studies attempting to decrease INR variability with low-dose daily vitamin K supplementation showed no benefit."
]
},
{
"type":"p",
"hlId":"20323c",
"children":[
"Bleeding is the most significant complication in patients treated with warfarin, occurring in 1% to 3% of patients per year. The risk is higher at warfarin initiation and during episodes of concurrent acute illness. The bleeding risk increases further in patients with an INR greater than 5. Independent of INR, bleeding risk is increased in patients older than 75 years or in those with previous stroke, gastrointestinal bleeding, or other chronic comorbidities. Concomitant aspirin, clopidogrel, and NSAID use increases the bleeding risk. The indication for antiplatelet agents for patients taking warfarin should be carefully reviewed, and dual antiplatelet therapy should be avoided if possible. Acetaminophen should be used instead of NSAIDs when feasible."
]
},
{
"type":"p",
"hlId":"27d96c",
"children":[
"Concern is often expressed when older adults begin oral anticoagulation, because age is an important risk factor for bleeding complications associated with warfarin. Oral anticoagulation may be prematurely excluded as a therapeutic option because of a perceived “fall risk.” The true risk of serious bleeding related to a fall while taking an anticoagulant is unclear, and small studies have not shown an increased risk of major bleeding in patients taking oral anticoagulants who were considered at high risk for falls. Risk factors for falls should be thoroughly evaluated and appropriate steps must be used for prevention (see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s10_4",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
"). Recommendations suggest that neither age nor fall risk is reason to withhold anticoagulation from a patient who meets clinical criteria warranting such therapy."
]
},
{
"type":"p",
"hlId":"1159a3",
"children":[
"Patients with asymptomatic INR elevation between 4.5 and 10 can often be managed by simply withholding warfarin. For INRs greater than 10 in patients without bleeding, oral vitamin K should be given. In patients experiencing life-threatening bleeding, in addition to intravenous vitamin K, 4-factor PCC should be given. Three-factor PCCs contain proteins C and S and factors II, IX, and X; 4-factor PCC also contains factor VII. In a clinical trial of VKA-related bleeding, 4-factor PCC was found to be noninferior to fresh frozen plasma for hemostatic efficacy. Four-factor PCC is preferred because of its rapid reversal of INR, rapid infusion and administration, and lack of volume overload. Recombinant factor VIIa is not recommended for warfarin reversal."
]
},
{
"type":"p",
"hlId":"ebe775",
"children":[
"Bridging therapy, using heparin or LMWH when warfarin is temporarily stopped for an invasive procedure, is not necessary for most patients and is associated with increased bleeding complications without additional anticoagulant benefit. The exception to this may be patients with VTE within the past 4 weeks, history of VTE during anticoagulant interruption for surgery, or a procedure with very high VTE risk, such as orthopedic surgery. Bridging is also indicated in patients with atrial fibrillation who have had a stroke or transient ischemic attack in the preceding year, in patients who have multiple risk factors for stroke (CHADS",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" score of 5-6), and in most patients with a mechanical heart valve."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"47298b",
"children":[
"Warfarin must be administered initially with at least 5 days of a parenteral anticoagulant (usually unfractionated or low-molecular-weight heparin) for the treatment of venous thromboembolism."
]
},
{
"type":"keypoint",
"hlId":"3d2256",
"hvc":true,
"children":[
"Bridging therapy, which uses unfractionated heparin or low-molecular-weight heparin during warfarin discontinuation before an invasive procedure, is not indicated for most patients because it is associated with more bleeding complications without any reduction in thrombotic events."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_5_2_2",
"title":{
"__html":"Direct Oral Anticoagulants"
},
"titleNode":{
"type":"section-title",
"hlId":"f39807",
"children":[
"Direct Oral Anticoagulants"
]
},
"children":[
{
"type":"p",
"hlId":"351d2a",
"children":[
"The DOACs have emerged as safe and effective treatment options for patients with VTE. In the 2016 CHEST guidelines and the 2020 ASH guidelines for DVT and PE treatment, DOACs are suggested as the treatment of choice for anticoagulation. The DOACs available for use in the United States are dabigatran, rivaroxaban, apixaban, and edoxaban. Dabigatran functions as a direct thrombin inhibitor, whereas the other agents are factor Xa inhibitors ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t36",
"wrapId":"13",
"children":[
"Table 36"
]
}
]
},
")"
]
},
". Dabigatran and edoxaban require initial treatment with a parenteral agent. Rivaroxaban and apixaban are approved as monotherapy for patients with DVT and PE."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_hm_t36"
]
},
{
"type":"p",
"hlId":"639931",
"children":[
"Routine coagulation studies do not reliably measure the degree of coagulation activity with DOACs. However, the thrombin time is quite sensitive to the presence of dabigatran and, if normal, indicates that the anticoagulant effect of dabigatran is no longer significant."
]
},
{
"type":"p",
"hlId":"043890",
"children":[
"Advantages of the DOACs include no need for routine monitoring, rapid onset of action, short half-life, fixed dosing, and fewer drug-drug interactions. DOACs are as effective as warfarin in preventing VTEs with less central nervous system bleeding, fatal bleeding, and use of blood product support. The bleeding risk is higher in patients taking concomitant aspirin or clopidogrel and is further increased in patients receiving dual antiplatelet therapy. No head-to-head trials have been performed comparing the various DOACs. Certain patient groups, including pregnant patients and those with mechanical heart valves, were excluded from the major trials of the DOACs. Some studies also excluded patients with BMI greater than 40 kg/m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" or weight greater than 120 kg (264.5 lb). Growing evidence shows that DOACs may be effective in this population, but caution is advised. Nonadherent patients should not be treated with DOACs. In patients with low-risk APLAS, the role of DOACs remains unclear, but they should be avoided in patients with high-risk disease. In patients with concern for gastrointestinal bleeding, dabigatran may not be preferred because of an increased rate of dyspepsia and gastrointestinal bleeding compared with warfarin."
]
},
{
"type":"p",
"hlId":"45c3c8",
"children":[
"All the DOACs are at least partially eliminated through the kidney (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t36",
"wrapId":"14",
"children":[
"Table 36"
]
}
]
},
")"
]
},
", and dose adjustment may be required in patients with advanced chronic kidney disease. Apixaban has the lowest renal elimination rate and is approved for patients undergoing dialysis; however, caution should be used. Data from a 2019 systematic review and meta-analysis suggest that DOACs may be preferred in patients with early stage chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
") and atrial fibrillation. Additionally, the risk of bleeding with DOACs appears to be no worse than with VKAs. DOACs should be used with caution or avoided in patients with Child-Pugh class B or C liver disease."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_b_hm_t36"
]
},
{
"type":"p",
"hlId":"ee64fa",
"children":[
"Bridging therapy is typically unnecessary in patients taking DOACs. Discontinuation of the DOAC depends on the half-life of the drug, the type of procedure, and the patient's kidney function. DOACs should be stopped 24 to 48 hours before surgery with moderate bleeding risk and 72 hours before surgery with higher bleeding risk. In patients with impaired kidney function, DOACs should be stopped earlier. For procedures with low bleeding risk, DOACs can be resumed promptly when effective hemostasis is secured. For procedures with higher rates of bleeding, reinstitution is usually delayed 2 to 3 days."
]
},
{
"type":"p",
"hlId":"2684cb",
"children":[
"The standard approach to patients experiencing bleeding involves hemodynamic monitoring and resuscitation with fluid and blood products. Activated charcoal can be considered if the DOAC was ingested recently (<6 hours). Hemodialysis can be considered with dabigatran therapy if new kidney disease is found. For patients with life-threatening bleeding who are taking an oral direct Xa inhibitor, the ASH suggests stopping the oral direct Xa inhibitor and considering treatment with either 4-factor PCC or andexanet alfa (off-label use for edoxaban). Experts recommend caution in using andexanet alfa and restricting its use to patients receiving anti-Xa anticoagulants who are experiencing life-threatening bleeding because of the high cost, significant risk of complications, and lack of data comparing the use of andexanet alfa to PCC. Idarucizumab is an FDA-approved monoclonal antibody fragment that binds free and thrombin-bound dabigatran and neutralizes its activity. Idarucizumab was found to be safe and effective in reversing the anticoagulant effects of dabigatran in patients who experienced serious, life-threatening bleeding determined to require a reversal agent or who required an urgent invasive procedure. Its use is recommended in the ASH 2018 guidelines on VTE treatment. If idarucizumab is not available, activated PCC is an alternative for patients with dabigatran-associated major bleeding."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e89ee8",
"children":[
"Dabigatran, rivaroxaban, apixaban, and edoxaban have a rapid onset of activity, no need for laboratory monitoring, and a therapeutic effect that is less likely than warfarin to be influenced by changes in diet or medications."
]
},
{
"type":"keypoint",
"hlId":"178338",
"children":[
"Direct oral anticoagulants (DOACs) are as effective as warfarin in preventing and treating venous thromboembolism; although the overall rate of bleeding is comparable, patients taking a DOAC have less central nervous system bleeding and less fatal bleeding."
]
},
{
"type":"keypoint",
"hlId":"6290f6",
"children":[
"The direct oral anticoagulants should not be used in patients with valvular heart disease, severe obesity, pregnancy, high-risk antiphospholipid antibody syndrome, or nonadherent patients."
]
},
{
"type":"keypoint",
"hlId":"99b2f4",
"children":[
"Direct oral anticoagulants are as effective as low-molecular-weight heparin in managing venous thromboembolism in patients with cancer."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s9_6",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Agnelli G, Becattini C, Meyer G, et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599-1607. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32223112",
"target":"_blank"
},
"children":[
"PMID: 32223112"
]
},
" doi:10.1056/NEJMoa1915103"
]
},
{
"type":"reference",
"children":[
"Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94:697-709. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30916798",
"target":"_blank"
},
"children":[
"PMID: 30916798"
]
},
" doi:10.1002/ajh.25475"
]
},
{
"type":"reference",
"children":[
"Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010-21. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29791828",
"target":"_blank"
},
"children":[
"PMID: 29791828"
]
},
" doi:10.1056/NEJMra1705454"
]
},
{
"type":"reference",
"children":[
"Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: A systematic review and meta-analysis. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M19-0087",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;171:181-89. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31307056",
"target":"_blank"
},
"children":[
"PMID: 31307056"
]
}
]
},
{
"type":"reference",
"children":[
"January CT, Wann LS, Calkins H, et al; Writing Group Members. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2019;16:e66-e93. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30703530",
"target":"_blank"
},
"children":[
"PMID: 30703530"
]
},
" doi:10.1016/j.hrthm.2019.01.024"
]
},
{
"type":"reference",
"children":[
"Kearon C, Kahn SR. Long-term treatment of venous thromboembolism. Blood. 2020;135:317-25. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31917402",
"target":"_blank"
},
"children":[
"PMID: 31917402"
]
},
" doi:10.1182/blood.2019002364"
]
},
{
"type":"reference",
"children":[
"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31381464",
"target":"_blank"
},
"children":[
"PMID: 31381464"
]
},
" doi:10.1200/JCO.19.01461"
]
},
{
"type":"reference",
"children":[
"Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693-4738. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33007077",
"target":"_blank"
},
"children":[
"PMID: 33007077"
]
},
" doi:10.1182/bloodadvances.2020001830"
]
},
{
"type":"reference",
"children":[
"Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365-71. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30002145",
"target":"_blank"
},
"children":[
"PMID: 30002145"
]
},
" doi:10.1182/blood-2018-04-848333"
]
},
{
"type":"reference",
"children":[
"Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2:3198-3225. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30482763",
"target":"_blank"
},
"children":[
"PMID: 30482763"
]
},
" doi:10.1182/bloodadvances.2018022954"
]
},
{
"type":"reference",
"children":[
"Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and Expert Panel report. Chest. 2021:S0012-3692(21)01506-3. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34352278",
"target":"_blank"
},
"children":[
"PMID: 34352278"
]
},
" doi:10.1016/j.chest.2021.07.055"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_hm_t28":{
"id":"mk19_b_hm_t28",
"number":28,
"bookId":"hm",
"title":{
"__html":"Conditions Associated With Acquired Decreased Anticoagulant Factor Levels"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"bc27aa",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 28. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t28"
}
]
},
"Conditions Associated With Acquired Decreased Anticoagulant Factor Levels"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f9aef",
"class":"col hd l",
"children":[
"Coagulation Factor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec4f20",
"class":"col hd l",
"children":[
"Acquired Condition"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20380f",
"class":"cell txt l",
"children":[
"Protein C"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e69dbb",
"class":"cell txt l",
"children":[
"Acute thrombosis"
]
},
" ",
{
"type":"p",
"hlId":"09177c",
"class":"cell txt l",
"children":[
"Warfarin therapy"
]
},
" ",
{
"type":"p",
"hlId":"21be40",
"class":"cell txt l",
"children":[
"Liver disease"
]
},
" ",
{
"type":"p",
"hlId":"e21f3d",
"class":"cell txt l",
"children":[
"Protein-losing enteropathy"
]
},
" ",
{
"type":"p",
"hlId":"528499",
"class":"cell txt l",
"children":[
"Disseminated intravascular coagulation"
]
},
" ",
{
"type":"p",
"hlId":"91cfff",
"class":"cell txt l",
"children":[
"Nephrotic syndrome"
]
},
" ",
{
"type":"p",
"hlId":"0d0e12",
"class":"cell txt l",
"children":[
"Vitamin K deficiency"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"33a250",
"class":"cell txt l",
"children":[
"Protein S"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e69dbb",
"class":"cell txt l",
"children":[
"Acute thrombosis"
]
},
" ",
{
"type":"p",
"hlId":"09177c",
"class":"cell txt l",
"children":[
"Warfarin therapy"
]
},
" ",
{
"type":"p",
"hlId":"21be40",
"class":"cell txt l",
"children":[
"Liver disease"
]
},
" ",
{
"type":"p",
"hlId":"c8c982",
"class":"cell txt l",
"children":[
"Inflammatory states"
]
},
" ",
{
"type":"p",
"hlId":"eccad4",
"class":"cell txt l",
"children":[
"Estrogens (contraceptives, pregnancy, postpartum state, hormone replacement therapy)"
]
},
" ",
{
"type":"p",
"hlId":"e21f3d",
"class":"cell txt l",
"children":[
"Protein-losing enteropathy"
]
},
" ",
{
"type":"p",
"hlId":"91cfff",
"class":"cell txt l",
"children":[
"Nephrotic syndrome"
]
},
" ",
{
"type":"p",
"hlId":"528499",
"class":"cell txt l",
"children":[
"Disseminated intravascular coagulation"
]
},
" ",
{
"type":"p",
"hlId":"abc5a5",
"class":"cell txt l",
"children":[
"HIV"
]
},
" ",
{
"type":"p",
"hlId":"575d9c",
"class":"cell txt l",
"children":[
"L–asparaginase chemotherapy"
]
},
" ",
{
"type":"p",
"hlId":"0d0e12",
"class":"cell txt l",
"children":[
"Vitamin K deficiency"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f453e0",
"class":"cell txt l",
"children":[
"Antithrombin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e69dbb",
"class":"cell txt l",
"children":[
"Acute thrombosis"
]
},
" ",
{
"type":"p",
"hlId":"c17b64",
"class":"cell txt l",
"children":[
"Heparin therapy"
]
},
" ",
{
"type":"p",
"hlId":"21be40",
"class":"cell txt l",
"children":[
"Liver disease"
]
},
" ",
{
"type":"p",
"hlId":"91cfff",
"class":"cell txt l",
"children":[
"Nephrotic syndrome"
]
},
" ",
{
"type":"p",
"hlId":"e21f3d",
"class":"cell txt l",
"children":[
"Protein-losing enteropathy"
]
},
" ",
{
"type":"p",
"hlId":"528499",
"class":"cell txt l",
"children":[
"Disseminated intravascular coagulation"
]
},
" ",
{
"type":"p",
"hlId":"1123db",
"class":"cell txt l",
"children":[
"ECMO (extra corporeal membrane circulation) and hemodialysis"
]
},
" ",
{
"type":"p",
"hlId":"575d9c",
"class":"cell txt l",
"children":[
"L–asparaginase chemotherapy"
]
},
" ",
{
"type":"p",
"hlId":"435aea",
"class":"cell txt l",
"children":[
"Severe trauma or burns"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_hm_t29":{
"id":"mk19_b_hm_t29",
"number":29,
"bookId":"hm",
"title":{
"__html":"Khorana Score<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f8bc4a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 29. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t29"
}
]
},
"Khorana Score",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a7945",
"class":"col hd l",
"children":[
"Risk Factor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75dd5f",
"class":"col hd l",
"children":[
"Points"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5a9f55",
"class":"cell txt l",
"children":[
"Site of cancer"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d4be4",
"class":"cell txt li",
"children":[
"Very high risk (stomach, pancreas)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57d79d",
"class":"cell txt li",
"children":[
"High risk (lung, lymphoma, gynecologic, bladder, testicular)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80fb71",
"class":"cell txt l",
"children":[
"BMI >35"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c76c3a",
"class":"cell txt l",
"children":[
"Hemoglobin level <10 g/dL (100 g/L) (or use of erythrocyte growth factors)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2082df",
"class":"cell txt l",
"children":[
"Leukocyte count >11,000/μL (11 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) (before chemotherapy)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f16b7",
"class":"cell txt l",
"children":[
"Platelet count >350,000/μL (350 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) (before chemotherapy)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Low-risk = 0 points; intermediate-risk = 1-2 points; high-risk = >3 points."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"The Khorana score assesses venous thromboembolism risk in patients with cancer."
]
]
},
"mk19_b_hm_t30":{
"id":"mk19_b_hm_t30",
"number":30,
"bookId":"hm",
"title":{
"__html":"Diagnosis of Antiphospholipid Antibody Syndrome<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9fa101",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 30. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t30"
}
]
},
"Diagnosis of Antiphospholipid Antibody Syndrome",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe5718",
"class":"col hd l",
"children":[
"Vascular Thrombosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca474d",
"class":"col hd l",
"children":[
"Pregnancy Morbidity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf28c5",
"class":"col hd l",
"children":[
"Laboratory Criteria",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2922ab",
"class":"cell txt l",
"children":[
"One or more objectively confirmed episodes of arterial, venous, or small vessel thrombosis occurring in any tissue or organ"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6557c6",
"class":"cell txt l",
"children":[
"One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation; or"
]
},
" ",
{
"type":"p",
"hlId":"6fd64e",
"class":"cell txt l",
"children":[
"One or more premature births of a morphologically normal neonate before the 34th week of gestation because of eclampsia, pre-eclampsia, or placental insufficiency; or"
]
},
" ",
{
"type":"p",
"hlId":"f3acf4",
"class":"cell txt l",
"children":[
"Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"309980",
"class":"cell txt l",
"children":[
"Lupus anticoagulant, detected according to the guidelines of the International Society on Thrombosis and Haemostasis"
]
},
" ",
{
"type":"p",
"hlId":"e21be6",
"class":"cell txt l",
"children":[
"Anticardiolipin antibody of IgG and/or IgM isotype, present in medium or high titer (greater than 40 GPL or MPL, or greater than the 99th percentile), measured by a standardized ELISA"
]
},
" ",
{
"type":"p",
"hlId":"c08f12",
"class":"cell txt l",
"children":[
"Anti-β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-glycoprotein-1 antibody of IgG and/or IgM isotype, present in titer greater than the 99th percentile, measured by a standardized ELISA"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ELISA = enzyme-linked immunosorbent assay; GPL = specificity for IgG phospholipid antigens; MPL = specificity for IgM phospholipid antigens."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Diagnosis is based on the presence of vascular thrombosis OR pregnancy morbidity PLUS relevant laboratory criteria."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"The presence of one or more of the following antiphospholipid antibodies on two or more occasions at least 12 weeks apart."
]
]
},
"mk19_b_hm_t31":{
"id":"mk19_b_hm_t31",
"number":31,
"bookId":"hm",
"title":{
"__html":"Wells Criteria for Deep Venous Thrombosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6fc884",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 31. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t31"
}
]
},
"Wells Criteria for Deep Venous Thrombosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b234b5",
"class":"col hd l",
"children":[
"Clinical Characteristic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75dd5f",
"class":"col hd l",
"children":[
"Points"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"748ba7",
"class":"cell txt l",
"children":[
"Active cancer (treatment within the previous 6 months or current palliative treatment)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4807a7",
"class":"cell txt l",
"children":[
"Paralysis, paresis, or recent immobilization of the lower extremities"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d06b86",
"class":"cell txt l",
"children":[
"Recently bedridden for ≥3 days, or major surgery within previous 12 weeks requiring anesthesia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8b6580",
"class":"cell txt l",
"children":[
"Swelling of the entire leg"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6db4ae",
"class":"cell txt l",
"children":[
"Localized tenderness along the deep venous system"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"61d1b1",
"class":"cell txt l",
"children":[
"Calf swelling ≥3 cm larger than on asymptomatic side (measured 10 cm below tibial tuberosity)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea56f1",
"class":"cell txt l",
"children":[
"Pitting edema confined to symptomatic leg"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f91db",
"class":"cell txt l",
"children":[
"Collateral superficial veins (nonvaricose)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2688e",
"class":"cell txt l",
"children":[
"Previously documented deep venous thrombosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701544",
"class":"cell txt l",
"children":[
"+1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb3d0d",
"class":"cell txt l",
"children":[
"Alternative diagnosis at least as likely"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"02e3c1",
"class":"cell txt l",
"children":[
"−2"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"0-1 points = DVT unlikely; obtain D-dimer assay. If the result is negative, no further evaluation; if the D-dimer is elevated, obtain Doppler ultrasonography."
],
[
">1 point = DVT likely; obtain Doppler ultrasonography."
],
[
"Reprinted with permission from Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"D"
]
},
"-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349:1227-35. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/14507948",
"target":"_blank"
},
"children":[
"PMID: 14507948"
]
},
" doi:10.1056/NEJMoa023153 Reprinted with permission from Massachusetts Medical Society."
]
]
},
"mk19_b_hm_t32":{
"id":"mk19_b_hm_t32",
"number":32,
"bookId":"hm",
"title":{
"__html":"Wells Criteria for Pulmonary Embolism"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"5767a0",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 32. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t32"
}
]
},
"Wells Criteria for Pulmonary Embolism"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"03df89",
"class":"col hd l",
"children":[
"Variables"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75dd5f",
"class":"col hd l",
"children":[
"Points"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"9af665",
"class":"col hd l",
"children":[
"Symptoms and Signs"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3a8db",
"class":"cell txt l",
"children":[
"Hemoptysis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2805c",
"class":"cell txt l",
"children":[
"Heart rate >100/min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"600864",
"class":"cell txt l",
"children":[
"1.5"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"345ecb",
"class":"cell txt l",
"children":[
"Clinical signs and symptoms of DVT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"16d2b3",
"class":"col hd l",
"children":[
"History"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5775f7",
"class":"cell txt l",
"children":[
"Previously documented DVT or PE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"600864",
"class":"cell txt l",
"children":[
"1.5"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"544340",
"class":"cell txt l",
"children":[
"Active cancer"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a75def",
"class":"cell txt l",
"children":[
"Bedridden ≥3 days or major surgery in previous 4 weeks"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"600864",
"class":"cell txt l",
"children":[
"1.5"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"6311ae",
"class":"col hd l",
"children":[
"Other"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b226b",
"class":"cell txt l",
"children":[
"PE is most likely diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DVT = deep venous thrombosis; PE = pulmonary embolism."
],
[
"≤4 points = PE unlikely; obtain D-dimer."
],
[
"4-6 points = moderate possibility of PE."
],
[
">6 points = high probability of PE."
],
[
"Data from Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416-20. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/10744147",
"target":"_blank"
},
"children":[
"PMID: 10744147"
]
}
]
]
},
"mk19_b_hm_t33":{
"id":"mk19_b_hm_t33",
"number":33,
"bookId":"hm",
"title":{
"__html":"Pulmonary Embolism Rule-Out Criteria for Predicting Probability of Pulmonary Embolism in Patients With Low Pretest Probability"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"081cdf",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 33. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t33"
}
]
},
"Pulmonary Embolism Rule-Out Criteria for Predicting Probability of Pulmonary Embolism in Patients With Low Pretest Probability"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b234b5",
"class":"col hd l",
"children":[
"Clinical Characteristic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66b012",
"class":"col hd l",
"children":[
"Meets Criterion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41be73",
"class":"col hd l",
"children":[
"Does Not Meet Criterion"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dcbd12",
"class":"cell txt l",
"children":[
"Age <50 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aaff8b",
"class":"cell txt l",
"children":[
"Initial heart rate <100 beats/min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6d6c7",
"class":"cell txt l",
"children":[
"Initial oxygen saturation >94% on room air"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05b5f1",
"class":"cell txt l",
"children":[
"No unilateral leg swelling"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46a308",
"class":"cell txt l",
"children":[
"No hemoptysis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42560e",
"class":"cell txt l",
"children":[
"No surgery or trauma within 4 weeks"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4290a",
"class":"cell txt l",
"children":[
"No history of venous thromboembolism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4a561a",
"class":"cell txt l",
"children":[
"No estrogen use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Pretest probability with score of 0 is <1%."
],
[
"Reprinted with permission from Raja AS, Greenberg JO, Qaseem A, et al; Clinical Guidelines Committee of the American College of Physicians. Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the clinical guidelines committee of the American College of Physicians. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M14-1772",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2015;163:701-11. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26414967",
"target":"_blank"
},
"children":[
"PMID: 26414967"
]
},
" Copyright 2015 American College of Physicians."
]
]
},
"mk19_b_hm_t34":{
"id":"mk19_b_hm_t34",
"number":34,
"bookId":"hm",
"title":{
"__html":"Simplified Pulmonary Embolism Severity Index (PESI)"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"cd7fad",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 34. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t34"
}
]
},
"Simplified Pulmonary Embolism Severity Index (PESI)"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47c148",
"class":"col hd l",
"children":[
"Variable"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"340e0f",
"class":"col hd l",
"children":[
"Simplified PESI",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" Score"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a24fae",
"class":"cell txt l",
"children":[
"Age >80 y"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"07089d",
"class":"cell txt l",
"children":[
"History of cancer"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71a55a",
"class":"cell txt l",
"children":[
"Chronic cardiopulmonary disease",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eaba6d",
"class":"cell txt l",
"children":[
"Pulse ≥110/min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3bf6ae",
"class":"cell txt l",
"children":[
"SBP <100 mm Hg"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba014b",
"class":"cell txt l",
"children":[
"Arterial oxyhemoglobin saturation level <90%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"A total point score is obtained by adding the points. The score corresponds with the following risk classes: 0 = low risk; ≥1 = high risk."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Combined variable of history of heart failure and history of chronic lung disease."
],
[
"Reprinted with permission from Fermann GJ, Erkens PM, Prins MH, et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. Acad Emerg Med. 2015;22:299-307. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25716463",
"target":"_blank"
},
"children":[
"PMID: 25716463"
]
},
" doi:10.1111/acem.12615"
]
]
},
"mk19_b_hm_t35":{
"id":"mk19_b_hm_t35",
"number":35,
"bookId":"hm",
"title":{
"__html":"Duration of Anticoagulant Therapy for Venous Thromboembolism<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"79f9fc",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 35. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t35"
}
]
},
"Duration of Anticoagulant Therapy for Venous Thromboembolism",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89e6fe",
"class":"col hd l",
"children":[
"Type of Thrombotic Event"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c10f2d",
"class":"col hd l",
"children":[
"Duration of Anticoagulant Therapy"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b01bf7",
"class":"cell txt l",
"children":[
"Superficial vein thrombophlebitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32f593",
"class":"cell txt l",
"children":[
"No anticoagulation suggested"
]
},
" ",
{
"type":"p",
"hlId":"59d8d8",
"class":"cell txt l",
"children":[
"Treat with supportive care (analgesia, warm compresses, and NSAIDs) and image if symptoms progress"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfedb5",
"class":"cell txt l",
"children":[
"Superficial vein thrombosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"245be0",
"class":"cell txt l",
"children":[
"ASH: Anticoagulation for 6 weeks if ≥5 cm in length, close to the deep venous system, or other thrombophilic risk factors exist"
]
},
" ",
{
"type":"p",
"hlId":"7ba3af",
"class":"cell txt l",
"children":[
"CHEST: Fondaparinux for 45 days if increased risk for clot progression (extensive SVT; involvement above the knee; severe symptoms; involvement of the greater saphenous vein; history of DVT, PE, or SVT; active cancer; recent surgery)"
]
},
" ",
{
"type":"p",
"hlId":"f35048",
"class":"cell txt l",
"children":[
"If not anticoagulated, follow up in 1 week and image if symptoms are persistent or worsening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9f993",
"class":"cell txt l",
"children":[
"Distal leg DVT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1e7af",
"class":"cell txt li",
"children":[
"No severe symptoms or risk factors for extension (positive D-dimer, close to proximal veins, multiple veins involved, >5 cm clot, active cancer, previous VTE, hospitalization, COVID-19, unprovoked)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"430f0f",
"class":"cell txt l",
"children":[
"Serial imaging over 2 weeks"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2cc38",
"class":"cell txt li",
"children":[
"Severe symptoms or risk factors for extension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47fde1",
"class":"cell txt l",
"children":[
"3-6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0adf97",
"class":"cell txt l",
"children":[
"Proximal leg DVT or PE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f3b45",
"class":"cell txt li",
"children":[
"Provoked (by surgery, trauma, immobility)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"156c07",
"class":"cell txt l",
"children":[
"ASH: 3-6 months"
]
},
" ",
{
"type":"p",
"hlId":"d67395",
"class":"cell txt l",
"children":[
"CHEST: 3 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cefc09",
"class":"cell txt li",
"children":[
"Unprovoked"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbede",
"class":"cell txt l",
"children":[
"Extended",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e58fa",
"class":"cell txt li",
"children":[
"Recurrent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51eaca",
"class":"cell txt l",
"children":[
"Duration of therapy depends on whether VTE events were provoked or unprovoked"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"84086e",
"class":"cell txt l",
"children":[
"Upper extremity DVT, proximal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"320b1d",
"class":"cell txt l",
"children":[
"3 months or as long as a central venous catheter remains in place"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4623c",
"class":"cell txt l",
"children":[
"Cancer-associated DVT or PE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0bba16",
"class":"cell txt l",
"children":[
"As long as the cancer is active or being treated"
]
},
" ",
{
"type":"p",
"hlId":"2c8ea8",
"class":"cell txt l",
"children":[
"ASCO/ASH: LMWH or DOACs are the preferred anticoagulants",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" ",
{
"type":"p",
"hlId":"f6fccc",
"class":"cell txt l",
"children":[
"CHEST: Apixaban, edoxaban, or rivaroxaban"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d20d8c",
"class":"cell txt l",
"children":[
"Chronic thromboembolic pulmonary hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f23578",
"class":"cell txt l",
"children":[
"Extended"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ASCO = American Society of Clinical Oncology; ASH = American Society of Hematology; CHEST = The American College of Chest Physicians; DOAC = direct oral anticoagulant; DVT = deep venous thrombosis; LMWH = low-molecular-weight heparin; PE = pulmonary embolism; SVT = superficial vein thrombosis; VTE = venous thromboembolism."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Decisions regarding duration of anticoagulation must always weigh the risk of VTE recurrence, risk of bleeding, and patient preference."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Indicates long-term anticoagulation therapy with periodic (such as once per year) re-evaluation of the risks, benefits, and burdens of long-term therapy and discussion of new clinical study results and new anticoagulant drugs."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31381464",
"target":"_blank"
},
"children":[
"PMID: 31381464"
]
},
" doi:10.1200/JCO.19.01461"
],
[
"Data from Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693-4738. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33007077",
"target":"_blank"
},
"children":[
"PMID: 33007077"
]
},
" doi:10.1182/bloodadvances.2020001830; and Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160:e545-e608. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34352278",
"target":"_blank"
},
"children":[
"PMID: 34352278"
]
},
" doi:10.1016/j.chest.2021.07.055"
]
]
},
"mk19_b_hm_t36":{
"id":"mk19_b_hm_t36",
"number":36,
"bookId":"hm",
"title":{
"__html":"Key Features of the Direct Oral Anticoagulants"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"000510",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 36. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t36"
}
]
},
"Key Features of the Direct Oral Anticoagulants"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"18ceb2",
"class":"col hd l",
"children":[
"Dabigatran"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f8e1b",
"class":"col hd l",
"children":[
"Rivaroxaban"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c578cb",
"class":"col hd l",
"children":[
"Apixaban"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2701d0",
"class":"col hd l",
"children":[
"Edoxaban"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3660ce",
"class":"cell txt l",
"children":[
"Class of anticoagulant"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71b98f",
"class":"cell txt l",
"children":[
"Direct factor IIa inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8422fa",
"class":"cell txt l",
"children":[
"Direct factor Xa inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8422fa",
"class":"cell txt l",
"children":[
"Direct factor Xa inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8422fa",
"class":"cell txt l",
"children":[
"Direct factor Xa inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ce762a",
"class":"cell txt l",
"children":[
"T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"max"
]
},
" (h)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98c6f2",
"class":"cell txt l",
"children":[
"1-2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f74ed3",
"class":"cell txt l",
"children":[
"Half-life (h)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b2ff7",
"class":"cell txt l",
"children":[
"12-17"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a089a8",
"class":"cell txt l",
"children":[
"7-11"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dab152",
"class":"cell txt l",
"children":[
"9-14"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c59920",
"class":"cell txt l",
"children":[
"9-11"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8ad70",
"class":"cell txt l",
"children":[
"Protein binding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62eb2d",
"class":"cell txt l",
"children":[
"35%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b8185",
"class":"cell txt l",
"children":[
"95%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3fceea",
"class":"cell txt l",
"children":[
"87%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0da365",
"class":"cell txt l",
"children":[
"54%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e277a",
"class":"cell txt l",
"children":[
"Renal elimination"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab7ac8",
"class":"cell txt l",
"children":[
"80%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4001d1",
"class":"cell txt l",
"children":[
"66% (33% as active metabolite)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae0ce6",
"class":"cell txt l",
"children":[
"25%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62eb2d",
"class":"cell txt l",
"children":[
"35%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3143c0",
"class":"cell txt l",
"children":[
"FDA-approved indications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2d4c1",
"class":"cell txt l",
"children":[
"Atrial fibrillation"
]
},
" ",
{
"type":"p",
"hlId":"42e8af",
"class":"cell txt l",
"children":[
"VTE treatment"
]
},
" ",
{
"type":"p",
"hlId":"e6b4fc",
"class":"cell txt l",
"children":[
"VTE prevention",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2d4c1",
"class":"cell txt l",
"children":[
"Atrial fibrillation"
]
},
" ",
{
"type":"p",
"hlId":"fa00c7",
"class":"cell txt l",
"children":[
"VTE treatment",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"e6b4fc",
"class":"cell txt l",
"children":[
"VTE prevention",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2d4c1",
"class":"cell txt l",
"children":[
"Atrial fibrillation"
]
},
" ",
{
"type":"p",
"hlId":"fa00c7",
"class":"cell txt l",
"children":[
"VTE treatment",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"e6b4fc",
"class":"cell txt l",
"children":[
"VTE prevention",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2d4c1",
"class":"cell txt l",
"children":[
"Atrial fibrillation"
]
},
" ",
{
"type":"p",
"hlId":"42e8af",
"class":"cell txt l",
"children":[
"VTE treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7f13d",
"class":"cell txt l",
"children":[
"Reversal agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"abca3e",
"class":"cell txt l",
"children":[
"Idarucizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"055040",
"class":"cell txt l",
"children":[
"Andexanet alfa or 4f-PCC"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"055040",
"class":"cell txt l",
"children":[
"Andexanet alfa or 4f-PCC"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"530662",
"class":"cell txt l",
"children":[
"Andexanet alfa",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
" or 4f-PCC"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"4f-PCC = 4-factor prothrombin complex concentrate; h = hour; NA = not applicable; T",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"max"
]
},
" = time to maximum concentration; VTE = venous thromboembolism."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Approved as monotherapy for VTE."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Dabigatran is approved for prevention of recurrent VTE, as well as for VTE prevention after hip replacement surgery. Rivaroxaban and apixaban are also approved for prevention of recurrent VTE, as well as for VTE prevention after hip and knee replacement."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Andexanet alfa is used off label for reversal of edoxaban."
]
]
}
}
}